| Literature DB >> 21199698 |
James S Robertson1, Carolyn Nicolson, Ruth Harvey, Rachel Johnson, Diane Major, Kate Guilfoyle, Sarah Roseby, Robert Newman, Rebecca Collin, Chantal Wallis, Othmar G Engelhardt, John M Wood, Jianhua Le, Ramanunninair Manojkumar, Barbara A Pokorny, Jeanmarie Silverman, Rene Devis, Doris Bucher, Erin Verity, Catherine Agius, Sarina Camuglia, Chi Ong, Steven Rockman, Anne Curtis, Peter Schoofs, Olga Zoueva, Hang Xie, Xing Li, Zhengshi Lin, Zhiping Ye, Li-Mei Chen, Eduardo O'Neill, Amanda Balish, Aleksandr S Lipatov, Zhu Guo, Irina Isakova, Charles T Davis, Pierre Rivailler, Kortney M Gustin, Jessica A Belser, Taronna R Maines, Terrence M Tumpey, Xiyan Xu, Jacqueline M Katz, Alexander Klimov, Nancy J Cox, Ruben O Donis.
Abstract
Wild type human influenza viruses do not usually grow well in embryonated hens' eggs, the substrate of choice for the production of inactivated influenza vaccine, and vaccine viruses need to be developed specifically for this purpose. In the event of a pandemic of influenza, vaccine viruses need to be created with utmost speed. At the onset of the current A(H1N1) pandemic in April 2009, a network of laboratories began a race against time to develop suitable candidate vaccine viruses. Two approaches were followed, the classical reassortment approach and the more recent reverse genetics approach. This report describes the development and the characteristics of current pandemic H1N1 candidate vaccine viruses.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21199698 DOI： 10.1016/j.vaccine.2010.12.044
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641